Request Demo
Last update 29 May 2026
BMS-986315
Last update 29 May 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms BMS 986315 |
Target |
Action antagonists |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with BMS-986315NCT06094296
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04349267
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
100 Clinical Results associated with BMS-986315
Login to view more data
100 Translational Medicine associated with BMS-986315
Login to view more data
100 Patents (Medical) associated with BMS-986315
Login to view more data
100 Deals associated with BMS-986315
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 27 Nov 2023 | |
| Recurrent Non-Small Cell Lung Cancer | Phase 2 | Australia | 27 Nov 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 14 Jul 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 14 Jul 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Mexico | 14 Jul 2020 | |
| Neuralgia | Phase 1 | United States | 10 Oct 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 44 | (Part 1A BMS-986315-80 mg) | acnxgsaayf = trqufneaab khvoghvdho (bunjcgetnk, naebnnuoor - korwvzkpce) View more | - | 17 Dec 2025 | ||
(Part 1A BMS-986315-200 mg) | acnxgsaayf = mipdfztnum khvoghvdho (bunjcgetnk, gbgrpmjceo - fafivjjryu) View more | ||||||
Phase 2 | 1 | sdpugqykoy = skbyxhdhnd wodanylgju (ttwsjomvce, xwncycgqpp - yeiwlpnubw) View more | - | 16 Apr 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free